Latest News
News
AS inflammatory back pain criteria fall short in PsA
The presence or absence of back pain in patients with axial radiologic involvement did not affect prognosis, suggesting the value of considering...
Conference Coverage
Psoriasis pipeline is full of biologics
CHICAGO – “The IL-23 blockers are ideal for patients who want a few injections.”
News
FDA announces plan for biosimilar innovation and competition
One proposed step is to release a series of videos that explain key concepts about biosimilar and interchangeable products.
News
Extended data support ixekizumab for plaque psoriasis
An open-label, 4-year extension study of ixekizumab yields promising results.
Conference Coverage
Biosimilar switch accepted by most rheumatic disease patients
LIVERPOOL, ENGLAND – With health systems increasingly favoring biosimilars to biologics, the question is, are patients happy to make the switch?...
News
Elderly patients with psoriasis can benefit from biologics with low rates of adverse events
Age should not be the deciding factor in which psoriasis patients receive treatment with these powerful therapies, according to Italian...
Conference Coverage
Adalimumab strikes out for aortic inflammation in psoriasis
ORLANDO – Ustekinumab shows promise, but “we are still not certain.”
Conference Coverage
Checkpoint inhibitors in autoimmune disease: More flares, better cancer outcomes
AMSTERDAM –
Conference Coverage
Biologic efficacy differs in psoriatic arthritis by lymphocyte phenotype
News
Risankizumab impresses in phase 2 psoriatic arthritis trial